• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.

作者信息

Ali Suhail M, Leitzel Kim, Lipton Allan, Carney Walter P, Köstler Wolfgang J

出版信息

J Clin Oncol. 2009 Dec 20;27(36):e273; author reply e274-5. doi: 10.1200/JCO.2009.23.4674. Epub 2009 Nov 16.

DOI:10.1200/JCO.2009.23.4674
PMID:19917836
Abstract
摘要

相似文献

1
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.血清人表皮生长因子受体2（HER2）/neu检测对HER2/neu靶向治疗反应进行早期预测的价值仍未明确，值得在大型前瞻性试验中进一步研究。
J Clin Oncol. 2009 Dec 20;27(36):e273; author reply e274-5. doi: 10.1200/JCO.2009.23.4674. Epub 2009 Nov 16.
2
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.血清HER2/neu在接受曲妥珠单抗治疗的转移性乳腺癌患者无进展生存期监测及预测中的临床应用
Breast Cancer Res. 2005;7(4):R436-43. doi: 10.1186/bcr1020. Epub 2005 Apr 8.
3
[The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].[血清HER2/NEU在曲妥珠单抗治疗的乳腺癌中的预测及监测价值]
Acta Med Port. 2011 Jan-Feb;24(1):5-16. Epub 2011 Feb 28.
4
Clinical utility of serum human epidermal growth factor receptor 2 extracellular domain levels: stop the shilly-shally--it is time for a well-designed, large-scale prospective study.血清人表皮生长因子受体2细胞外结构域水平的临床应用：别再犹豫不决了——是时候开展一项设计完善的大规模前瞻性研究了。
J Clin Oncol. 2009 Dec 20;27(36):e286-7. doi: 10.1200/JCO.2009.24.5100. Epub 2009 Nov 16.
5
Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.血清HER2细胞外结构域评估在临床决策中的效用：曲妥珠单抗治疗转移性乳腺癌四项试验的汇总分析
J Clin Oncol. 2009 Apr 1;27(10):1685-93. doi: 10.1200/JCO.2008.16.8351. Epub 2009 Mar 2.
6
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.针对 HER2 靶向治疗耐药的策略演进：针对 PI3K/Akt/mTOR 通路。
Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015.
7
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.HER2/neu在乳腺癌中的作用：从预后的“敌人”到预测的“朋友”
Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62. doi: 10.1097/GCO.0b013e328012980a.
8
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.曲妥珠单抗-DM1 抗体药物偶联物治疗曲妥珠单抗治疗后人表皮生长因子受体 2（HER2）阳性乳腺癌的 II 期研究。
J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.
9
HER2-positive advanced breast cancer.人表皮生长因子受体2阳性晚期乳腺癌
Hematol Oncol Clin North Am. 2007 Apr;21(2):293-302. doi: 10.1016/j.hoc.2007.03.010.
10
HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?小且无淋巴结转移的乳腺癌患者（pT1a,b，N0，M0）中HER2-neu阳性：一个高危组？
Clin Adv Hematol Oncol. 2009 Sep;7(9):591-8.

引用本文的文献

1
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.血浆 HER2ECD 有望成为 HER2 阳性乳腺癌患者预后和预测反应的检测指标：一项随机研究的结果-SAKK 22/99。
BMC Cancer. 2020 Feb 11;20(1):114. doi: 10.1186/s12885-020-6594-0.
2
An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.曲妥珠单抗为基础的治疗转移性乳腺癌患者反应的血清 sHER2、CA15.3 和 CEA 水平作为生物标志物的更新评估。
PLoS One. 2020 Jan 7;15(1):e0227356. doi: 10.1371/journal.pone.0227356. eCollection 2020.
3
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
利用基因表达和癌症生物标志物为个性化医疗时代铺平道路。
Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235. doi: 10.1016/j.gpb.2016.11.005. Epub 2017 Aug 13.
4
Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.可溶性人表皮生长因子受体-2细胞外结构域在转移性乳腺癌中的预后预测价值
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1108-13. eCollection 2014.
5
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?循环HER2细胞外结构域：所有乳腺癌患者预后价值的特异性定量生物标志物？
Biomark Cancer. 2013 Aug 12;5:31-9. doi: 10.4137/BIC.S12389.
6
The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.血清 HER2/neu 对蒽环类和曲妥珠单抗为基础的新辅助化疗反应的预测价值。
J Breast Cancer. 2012 Jun;15(2):189-96. doi: 10.4048/jbc.2012.15.2.189. Epub 2012 Jun 28.
7
Challenges in the clinical utility of the serum test for HER2 ECD.HER2胞外域血清检测在临床应用中的挑战。
Biochim Biophys Acta. 2012 Aug;1826(1):199-208. doi: 10.1016/j.bbcan.2012.03.012. Epub 2012 Apr 3.